32
Participants
Start Date
May 31, 2007
Primary Completion Date
February 29, 2012
Study Completion Date
February 29, 2012
anti-thymocyte globulin
0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
cyclophosphamide
60mg/kg on days -5 and -4 from stem cell transplant
etoposide
60mg/kg on day -4 from stem cell transplant
fludarabine phosphate
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
melphalan
Melphalan 140 mg/m2 on day -4 from stem cell transplant
methotrexate
For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
sirolimus
"Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.~Pediatric Patients \<40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose"
tacrolimus
0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
allogeneic hematopoietic stem cell transplantation
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
hematopoietic stem cell transplantation
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
nonmyeloablative allogeneic hematopoietic stem cell transplantation
Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
peripheral blood stem cell transplantation
The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
total-body irradiation
1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
Banner Good Samaritan Medical Center, Phoenix
City of Hope Comprehensive Cancer Center, Duarte
National Cancer Institute (NCI)
NIH
City of Hope Medical Center
OTHER